ATE501710T1 - Somatostatin-analog-formulierungen - Google Patents

Somatostatin-analog-formulierungen

Info

Publication number
ATE501710T1
ATE501710T1 AT05818366T AT05818366T ATE501710T1 AT E501710 T1 ATE501710 T1 AT E501710T1 AT 05818366 T AT05818366 T AT 05818366T AT 05818366 T AT05818366 T AT 05818366T AT E501710 T1 ATE501710 T1 AT E501710T1
Authority
AT
Austria
Prior art keywords
formulations
somatostatin analog
somatostatin
administration
analog formulations
Prior art date
Application number
AT05818366T
Other languages
German (de)
English (en)
Inventor
Fredrik Joabsson
Markus Johnsson
Andreas Norlin
Fredrik Tiberg
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0500807A external-priority patent/GB0500807D0/en
Priority claimed from GB0507811A external-priority patent/GB0507811D0/en
Priority claimed from PCT/GB2005/002217 external-priority patent/WO2005117830A1/en
Priority claimed from GB0518878A external-priority patent/GB0518878D0/en
Application filed by Camurus Ab filed Critical Camurus Ab
Priority claimed from PCT/GB2005/004748 external-priority patent/WO2006075124A1/en
Application granted granted Critical
Publication of ATE501710T1 publication Critical patent/ATE501710T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT05818366T 2005-01-14 2005-12-09 Somatostatin-analog-formulierungen ATE501710T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0500807A GB0500807D0 (en) 2005-01-14 2005-01-14 Formulation
GB0507811A GB0507811D0 (en) 2005-04-18 2005-04-18 Formulation
PCT/GB2005/002217 WO2005117830A1 (en) 2004-06-04 2005-06-06 Liquid depot formulations
GB0518878A GB0518878D0 (en) 2005-09-15 2005-09-15 Formulations
PCT/GB2005/004748 WO2006075124A1 (en) 2005-01-14 2005-12-09 Somatostatin analogue formulations

Publications (1)

Publication Number Publication Date
ATE501710T1 true ATE501710T1 (de) 2011-04-15

Family

ID=40432504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05818366T ATE501710T1 (de) 2005-01-14 2005-12-09 Somatostatin-analog-formulierungen

Country Status (7)

Country Link
US (1) US8871712B2 (enExample)
EP (1) EP1843746B1 (enExample)
JP (1) JP5171262B2 (enExample)
AT (1) ATE501710T1 (enExample)
CA (1) CA2594711C (enExample)
DE (1) DE602005026998D1 (enExample)
PL (1) PL1843746T3 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
ES2343641T3 (es) 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
WO2006077362A1 (en) 2005-01-21 2006-07-27 Camurus Ab Pharmaceutical lipid compositions
CN101217940B (zh) * 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
CN103702662B (zh) * 2011-05-25 2018-07-20 卡穆鲁斯公司 控制释放肽制剂
CN104093399B (zh) * 2011-12-05 2018-03-13 卡穆鲁斯公司 鲁棒性控释肽制剂
CN104080478A (zh) * 2012-01-31 2014-10-01 参天制药株式会社 非水性液体组合物
AU2013265210B2 (en) * 2012-05-25 2016-09-15 Camurus Ab Somatostatin receptor agonist formulations
AU2017336199B2 (en) * 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
WO2018067987A1 (en) * 2016-10-06 2018-04-12 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
CA3045114A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
JP2021059680A (ja) * 2019-10-08 2021-04-15 花王株式会社 液晶組成物
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US595502A (en) * 1897-12-14 terpeningt
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5340802A (en) 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
CA2120359C (en) 1991-10-04 2000-12-26 Tomas Landh Particles, method of preparing said particles and uses thereof
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
AU685262B2 (en) 1994-03-30 1998-01-15 Gs Development Ab Use of fatty acid esters as bioadhesive substances
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
FR2725369B1 (fr) 1994-10-07 1997-01-03 Oreal Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire
AU702030B2 (en) 1995-10-12 1999-02-11 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP0975331A1 (en) 1997-04-17 2000-02-02 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
EP1600162A1 (en) 1998-12-22 2005-11-30 Eli Lilly & Company Shelf-stable formulation of glucagon-like peptide-1
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
CA2451432A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
US7622118B2 (en) 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
WO2005014162A1 (en) 2003-08-04 2005-02-17 Camurus Ab Method for improving the properties of amphiphile particles
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
GB0322033D0 (en) 2003-09-19 2003-10-22 Camurus Ab Composition
EP1682091B1 (en) 2003-11-07 2017-03-29 Camurus Ab Compositions of lipids and cationic peptides
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
EP1713446B1 (en) 2004-01-23 2010-12-01 Camurus Ab Ternary non-lamellar lipid compositions
EP1768650B1 (en) 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
JP5513713B2 (ja) 2004-08-04 2014-06-04 カムルス エービー 非層状分散を生じる組成物
WO2006075123A1 (en) 2005-01-14 2006-07-20 Camurus Ab Topical bioadhesive formulations
ES2343641T3 (es) 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
KR100983746B1 (ko) 2005-01-14 2010-09-24 카무러스 에이비 소마토스타틴 유사 제형
WO2006077362A1 (en) 2005-01-21 2006-07-27 Camurus Ab Pharmaceutical lipid compositions
CN101217940B (zh) 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
US8097239B2 (en) 2005-06-06 2012-01-17 Camurus Ab Controlled-release formulations
WO2007061896A1 (en) 2005-11-17 2007-05-31 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations

Also Published As

Publication number Publication date
JP5171262B2 (ja) 2013-03-27
US8871712B2 (en) 2014-10-28
PL1843746T3 (pl) 2011-09-30
CA2594711C (en) 2012-11-06
JP2008526933A (ja) 2008-07-24
DE602005026998D1 (de) 2011-04-28
CA2594711A1 (en) 2006-07-20
US20090069221A1 (en) 2009-03-12
EP1843746A1 (en) 2007-10-17
EP1843746B1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
DE602005026998D1 (de) Somatostatin-analog-formulierungen
PH12013502550A1 (en) Controlled release peptide formulations
DK1845942T3 (da) GNRH-analogformuleringer
PE20050919A1 (es) Agente endoparasiticida para administracion topica
MX2014006624A (es) Formulaciones peptidicas robustas de liberación controlada.
UY29004A1 (es) Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
ECSP10010184A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril-urea
ATE401054T1 (de) Flüssige depotformulierungen
UY27740A1 (es) Nuevos compuestos
NO20070983L (no) Stabil injiserbar blanding av alfa-tokoferylsuksinat, analoger og salter derav
ECSP067027A (es) Formulaciones acuosas pobres en espuma para la proteccion de las plantas
UY28510A1 (es) Compuestos quimicos
AR066583A1 (es) Derivados de 3,3-espiroindolinona
ECSP066898A (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
AR020016A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
BR0212028A (pt) Sistema terapêutico transdérmico (tts) com a substância ativa fentanila
AR019262A1 (es) Proceso para la preparacion de una formulacion que comprende una sustancia activa o sustancias activas asociadas con un portador, y formulacion preparadapor dicho proceso.
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
PA8584101A1 (es) Composicion antihelmintica e inyectable mejoradora de crecimiento
CL2008001684A1 (es) Uso de un agente estimulador seleccionado entre el grupo de acidos uronicos, mananos, sales e hidratos de los mismos y mezclas de dichos compuestos, que sirve para preparar una composicion biopesticida que comprende un microorganismo antagonista, donde dicho agente estimula las propiedades antagonistas de microorganismo antagonista. (divisional solictud 422-02)
EA201791166A1 (ru) Препараты с контролируемым высвобождением
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
PA8542601A1 (es) Bifenilcarboxamidas reductoras de lipidos
BR0311687A (pt) composições farmacêuticas estabilizadas com base em óleo de rìcino polioxietilado e método para a fabricação das mesmas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties